The FDAs announcment a couple days ago that it would not enforce exclusivity with compounders making cheaper, non-approved versions (the original versions) of KV's newly approved Makena appears to have been the final straw. Already under fire from patients, lawmakers, physicians, third-party payers, foundations, patient advocates, pundits and the Baja Marimba Band and the Mormon Tabernacle Choir, KV decided enough was enough and rolled back its list price from $1500 to $690. See St. Louis Biz and Pharmalot blog.
This is still quite a bit more than the compounder's $20-$30 per patient price but does represent a 55% decrease from the $1500 price point. Said KV Chief Exec Greg Davis,
We understand the concerns that key stakeholders raised under our original pricing structure. We also recognize the current budget challenges facing state Medicaid programs and other payers. In conjunction with our substantial reduction in price, it is our sincere hope that all committed stakeholders will take appropriate action to provide timely access to this important FDA-approved medication.
In other words, "Please don't go to the compounders. No Mas!"
Posted by Bruce Lehr April 1st 2011.